Cytokinetics Posts Cohort 3 Data From Aficamten Trial In Heart Disease Patients
Cytokinetics Incorporated (NASDAQ: CYTK) has announced
56 Biggest Movers From Friday
Gainers
Hour Loop, Inc. (NASDAQ: HOUR) shares jumped 99.8% to $7.99 after the company priced its IPO at $4 per share.
33 Stocks Moving In Friday’s Mid-Day Session
Gainers
Marin Software Incorporated (NASDAQ: MRIN) shares climbed 35.9% to $4.6899 after the company announced an integration with Amazon Ads' demand-side platform.
Cytokinetics, Royalty Pharma Report Funding Deals For Total Of Up To $450M
Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten
Royalty Pharma Purchases Royalties on Future Sales of Aficamten
Oppenheimer Initiates Coverage On Cytokinetics with Outperform Rating, Announces Price Target of $55
Oppenheimer analyst Justin Kim initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Outperform rating and announces Price Target of $55.
HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $69
HC Wainwright & Co. analyst Joseph Pantginis maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $62 to $69.
What 5 Analyst Ratings Have To Say About Cytokinetics
Analysts have provided the following ratings for Cytokinetics (NASDAQ:CYTK) within the last quarter:
JP Morgan Initiates Coverage On Cytokinetics with Overweight Rating, Announces Price Target of $58
JP Morgan analyst Anupam Rama initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Overweight rating and announces Price Target of $58.
Cytokinetics Announces Receipt Of Breakthrough Therapy Designation From FDA for Aficamten
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for aficamten for the treatment of symptomatic obstructive